Metabolomics is a high-throughput technology that captures the global metabolic state of an individual by simultaneously assaying an extensive set of lowmolecular-weight compounds (metabolites) within a biological sample 1 . Metabolites are thought to represent the intermediate products of a number of physiological processes that are influenced by mechanisms of disease, lifestyle choices, the surrounding environment and pharmacological treatments (FIG. 1) . In this sense, metabolites provide a more accurate representation of a disease phenotype than that provided by genetic variation, gene expression levels or protein levels, making metabolomics a powerful tool for identifying biomarkers for use in diagnosis, prognosis or prediction and monitoring of treatment efficacy 2 . Moreover, different clinical responses to therapy can result in different metabolite profiles 3 , suggesting that metabolomic profiling could help to identify patients who respond well to therapy, thereby improving the clinical management of rheumatic diseases.
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Metabolomic profiling has the potential to provide an alternative perspective on the altered molecular processes responsible for the onset and pathogenesis of various rheumatic diseases, which could be of paramount importance in the prevention of joint damage and disability. At the same time, metabolite levels reflect an individual's genetic makeup [4] [5] [6] [7] [8] [9] . The genetic contribution to metabolite levels and disease processes needs further research if metabolomic studies are going to reach their full potential. In the first part of this Review, we discuss various methodological aspects related to metabolomic profiling studies. In the second part, we present the metabolomic and genetic studies carried out to date on rheumatic diseases, discussing any potential links between discoveries from metabolic studies and genetic studies of some of the most common rheumatic diseases, including rheumatoid arthritis (RA), osteoarthritis (OA), psoriatic arthritis (PsA), gout and systemic lupus erythematosus (SLE).
Metabolomic profiling

Methodological considerations
Thousands of small molecules make up the human metabolome 10 ; however, the precise number of potentially detectable independent metabolites is unclear, and although it is now possible to characterize hundreds of known metabolites, the entire metabolome has yet to be fully covered. Bearing this in mind, there are several important points to consider when designing a metabolomic study. and plasma) are the most accessible biological samples as they are easy to collect by minimally invasive methods in patients and healthy individuals. There is also no need for additional grinding or fractionation with these types of biological sample. However, in patients with rheumatic diseases, urine and blood might not reflect the biochemical or physiopathological changes taking place in the joint.
Synovial fluid and tissues from either the joint or the bone are more relevant to pathogenesis than blood or urine in patients with rheumatic diseases. Synovial fluid samples are easy to collect from patients with RA or OA who have joint effusion, but are more difficult to collect from healthy individuals. This type of sample requires less processing and sample preparation than tissue-derived samples (such as cartilage or bone), but the metabolomic profile of synovial fluid might not fully represent the biochemical changes taking place in other joint tissues.
Tissues from cartilage or bone are useful when studying pathogenic processes in the joint. Unfortunately, collecting large numbers of such tissue samples (particularly from healthy individuals) is extremely challenging. Moreover, some techniques require manual and solvent extraction of tissue samples, followed by precipitation and further redissolving of the resulting dry residues, increasing the time and complexity of measuring metabolites in these tissues.
Targeted versus untargeted methods. The metabolome can be analysed by targeted and untargeted approaches 13, 14 ( FIG. 2) . Untargeted metabolomics techniques measure hundreds of metabolites, with the advantage of detecting previously unpredicted metabolic perturbations associated with a certain disease. Similar to genome-wide association studies (GWAS), no previous knowledge of biologically relevant metabolites is required when designing this type of experiment. Untargeted approaches are therefore useful for finding novel mechanisms or biomarkers. Targeted approaches, on the other hand, resemble candidate-gene association studies, in which small, predefined sets of genes (or in this case, metabolites) are measured, typically focusing on a few pathways of interest. The advantages of this kind of approach include a higher degree of sensitivity than untargeted approaches, absolute (instead of relative) quantification of metabolites and easy identification of compounds 13 .
Dealing with 'unknowns'. Another advantage of untargeted metabolomics techniques is their ability to provide quantification of metabolites of unknown chemical identity that can be detected and quantified reproducibly. These metabolites, the so-called 'unknowns' , are important to consider. Indeed, in biomedical research, the levels of many of these metabolites can strongly correlate with clinical phenotypes [15] [16] [17] , even if their functional link to the disease has yet to be unravelled. The majority of published metabolomic studies exclude 'unknowns' either by platform design 18 or at the analysis stage 19, 20 . Some researchers have tried to solve the problem of 'unknowns' by employing different computational methods. Genetic data are particularly useful for such endeavours, as several unknown metabolites are associated with genetic variants 5, 7 . These variants provide a clue as to the metabolic pathway the unknown metabolite is most likely to belong to. One novel functional metabolomics method integrates high-throughput genotyping data, metabolomic data and information on metabolic pathways derived from the literature to predict the identity of unknown metabolites 21 . The advantage of this method is that it can be applied to metabolomic databases obtained from commercial services, for which data on retention times, isotope patterns and fragmentation are not readily available.
Technological platform. Metabolites vary in size, polarity and concentration, making unbiased detection, identification and quantification of the whole metabolome technically challenging 10 . The main methods employed in metabolomic studies are NMR spectroscopy and mass spectrometry (MS) [22] [23] [24] (reviewed elsewhere 25 ). Briefly, NMR spectroscopy is a quantitative, non-discriminating, non-destructive technique that provides detailed information about solution-state molecular structures based on atom-centred nuclear interactions 26 . NMR spectroscopy has several advantages, including the possibility of performing high-throughput measurements, minimal requirements for sample preparation, high reproducibility of results, low cost per measurement, high speed of data acquisition and the non-discriminating and nondestructive nature of the technique 27, 28 . However, NMR spectroscopy has a relatively low level of sensitivity and can detect only metabolites at medium-to-high levels of abundance 29 . Alternatively, MS-based metabolomics provides highly selective and sensitive quantitative analyses with the potential to identify individual metabolites 30 . Within biological samples, metabolites are initially separated using chromatography (gas chromatography, capillary electrophoresis, liquid chromatography or ultraperformance liquid chromatography) and identified with a mass spectrometer 31, 32 , although pre-separation is not always required. Some commercially available MS kits, such as the Biocrates Absolute-IDQ Kit p150, directly sample metabolites from plates for quantitative analysis without pre-separation. Techniques based on gas chromatography-MS (GC-MS) and liquid chromatography-MS (LC-MS) provide metabolite separation in a time dimension, enabling the extraction of highly specific chemical information; however, these techniques also require preparation steps
Key points
• Although large-scale genome-wide association studies have identified many rheumatic disease-associated genetic variants, effect sizes are small (with the exception of HLA loci) • Metabolomics is a promising field for investigating the molecular pathogenesis of rheumatic diseases and for monitoring response to therapy, but only a few modest-sized studies have been conducted to date • The contribution made by genetic factors to the production of metabolites and to disease processes in general needs to be investigated if metabolomics studies are to reach their full potential • Integrating data from different omics studies, including metagenomics and proteomics, will help to increase our knowledge of pathways and diseases . Additionally, different platforms are better at detecting specific metabolites, making the parallel application of techniques such as GC-MS and LC-MS desirable to study the metabolome comprehensively.
Analytical considerations
Statistical techniques, data reduction and pathway analysis. Many statistical techniques can be employed in the analysis of metabolomic data 34 (FIG. 3) . The usual starting point for analysis is quality control of the metabolite data. Quality control can involve several steps, including data normalization to remove or reduce unwanted overall variation in the spectral data; standardization of the data, so that the data distribution has a mean of 0 when data is measured in a relative manner; and scaling of the data to account for differences in the concentration of metabolites, focusing on metabolites at medium or low concentrations. Next, univariate or multivariate statistical analyses are performed to identify candidate biomarkers.
In methods of univariate analysis such as linear regression models, generalized linear models, t-tests or ANOVA, each variable is examined separately. Such methods are adequate when the aim of the analysis is to identify metabolites associated with pathogenesis 34 . Stringent multiple testing corrections are normally applied (such as the Bonferroni correction or false discovery rate), which can obscure some biologically relevant observations. However, univariate analyses produce very solid and reproducible results despite the obvious limitations of these methods (such as false negatives).
Multivariate analysis is a powerful tool for finding biomarkers for classification and prediction of many aspects of disease, given that individual biomarkers might not be specific enough for a given trait. Multivariate methods include principal component analysis, partial least squares discriminant analysis, penalized regression models, random forest models and support vector machines 35 .
Principal component analysis is particularly useful to gain an overview of the data and to define previously unknown relationships between metabolites in a given physiological state. Alternatively, supervised methods such as partial least squares discriminant analysis or support vector machines can create models to classify metabolites. However, most multivariate methods require a complete data matrix, which introduces the problem of imputation of missing values.
Independent replication of metabolomics studies and follow-up functional studies are especially important to validate any biomarkers identified. Although biomarkers are useful for predicting the risk of developing a disease and for monitoring disease progression or therapeutic efficacy, the value of a biomarker increases substantially if it is causally involved in a disease. Multi-omics data cannot prove the causality of a metabolite in a particular disease, but can enable interesting modelling and statistical inference of causality, leading to further investigation. Genetic effects are, by definition, causal, so combining genetic and metabolomic data might enable the inference of causality networks for disease phenotypes. Metabolic associations can be difficult to understand in complex diseases 36 , but using omics technologies can help to decipher the biological meaning of otherwise obscure statistical associations. The benefits of using pathway and ontological analyses for genomics data have been extensively discussed 37, 38 . The Database for Annotation, Visualisation and Integrated Discovery (DAVID) v6.7 (REF. 39 ) and Ingenuity Pathway Analysis (IPA) 40 software can be used to identify the biological pathways that underly the associations between metabolite signatures and diseases. Indeed, such functional annotation tools (normally used for genomic or genetic studies) can be applied to genes identified by GWAS or transcriptomic studies as being associated with certain metabolites, providing information on the biological pathways linked to these disease-associated or drug-response-associated metabolites . 44 , MetaboLIGHTS 45 and The Metabolomics GWAS Server, among others. Moreover, web services now exist for metabolomic data processing, analysis and annotation, such as MetaboAnalyst.
Metabolomics meets genomics
A number of studies in the past few years have mapped genetic variations in plasma, serum and urine metabolites, highlighting the influence of genetics on these traits [4] [5] [6] [7] [8] [9] . Using metabolomics as a readout of molecular phenotypes is enabling the discovery of formerly undetected associations between diseases, genes and metabolic pathways. The number of published metabolomic studies has exponentially increased, with over 4,000 papers published in 2015 (as listed on PubMed), a figure not much lower than that of GWAS papers.
Metabolomics and rheumatic disease
In the past few years, various published studies have investigated the associations between metabolites and rheumatic diseases in humans (TABLE 1; see Supplementary information S1 (table) ). These studies show that patients with rheumatic diseases can be clearly distinguished from healthy individuals on the basis of the metabolic profile of their blood 18 or urine 46 . One study used a panel of 52 metabolites from circulating blood to distinguish patients with RA from healthy individuals and patients with PsA with a high degree of sensitivity (93%) and specificity (70%) 47 . Patients with RA and OA can be distinguished from healthy individuals by decreased levels of (branched-chain) amino acids 16, 48 and increased levels of 3-hydroxybutyrate and lactate 49 , and patients with SLE can be identified by changes in energy metabolism 50, 51 . Interestingly, similar metabolic changes also correlate with Figure 2 | Targeted versus untargeted metabolomics approaches. Two main approaches exist for carrying out metabolic profiling: targeted and untargeted. The scope of these two types of analysis is different and they both have advantages and disadvantages. Targeted metabolomics approaches have a low detection limit and enable the absolute quantification of the sample. However, targeted methods do not enable the discovery of unknown compounds. Untargeted metabolomics approaches provide a global view of a sample. The disadvantages of untargeted methods include the complex informatics required to interpret the results, the semi-quantitative nature of the methods and the need to validate any identified compounds. 45 . For instance, the response of patients with RA to anti-TNF therapy was predicted using urine metabolite profiles with a sensitivity of 88.9% and a specificity of 85.7% (REF 3) . Metabolomics studies also help to identify causal mechanisms of disease, for example by establishing a proinflammatory role for oestrogens in patients with RA and OA 54 . One study used metabolomic profiling to identify global metabolic defects that are associated with four different types of rheumatic disease (OA, RA, gout and ankylosing spondylitis) 55 . This approach identified a metabolic defect common to all four diseases that is due to the presence of joint inflammation and lesions, as well as a unique metabolic signature for each disease compared with healthy individuals 55 . These studies highlight the potential uses of metabolomics in biomarker discovery and treatment stratification; however, many of these studies base their conclusions on small sample sizes and lack replication and stringent correction for multiple testing. Future studies should address these issues to find reliable biomarkers of disease progression and response to treatment.
Data quality control
Genetics and rheumatic disease
Usually, there are three main aims behind any genetics study. The first is to identify proteins and pathways that are crucial to pathophysiology and increase our understanding of the condition. The second is to identify clinically relevant therapeutic targets that can prevent either the whole, or one aspect of a disease. Finally, the third aim is to identify a set of measurable variants to determine which individuals are at high risk of developing disease.
GWAS allow researchers to look for associations between common genetic variants (such as single nucleotide polymorphisms (SNPs), copy number variations (CNVs) and indels) and specific disease phenotypes. In the past few years, large-scale human GWAS of patients with OA (>18,000 participants 56 ) and RA (>100,000 participants 57 ) have identified a substantial number of loci in several common pathways associated with the prevalence, severity and progression of these rheumatic diseases. Combined data from more than 50 GWAS give a total of 303 SNPs in 186 genes, spanning all chromosomes, which are associated with at least one rheumatic disease (see Supplementary information S2 (figure) ). These studies reveal that rheumatic diseases share common genetic risk factors, such as mutations in TNFAIP3, which are associated with RA 57 , PsA 58 and SLE 59 . The common genetic basis of these diseases is a possible reason for their shared comorbidities 60 . Common genetic causes also lead to similar symptoms, hindering the precise diagnosis of these diseases.
Metabolomic studies reveal a more accurate picture of disease mechanisms than genetic studies (FIG. 1) , making it possible to use metabolomics to differentiate between diseases when genetics cannot. However, in many cases the molecular links between a gene or biochemical pathway and the disease in question remain unknown. Animal models have helped us to understand the mechanisms underlying some of the disease-risk genes identified for rheumatic diseases. Studies in knockout mice showed the effect of genetic deletion of Tnfaip3 on the inflammosome 61 , whereas the role of insulin-like growth factor-binding protein 3 (IGFBP3) in nuclear factor-κB (NF-κB) signalling and its subsequent effect on RA was investigated using mice with collagen-induced arthritis 62 . Work on Runx2 knockout mice with the medial meniscal tear model of OA explored the effect of runt-related transcription factor 2 (RUNX2) on OA by causing chondrocyte hypertrophy 63 . Such research into the mechanisms of rheumatic disease-related genes facilitates the discovery of potential therapeutic targets such as RUNX2 (REF. 64 ) and IGFBP3 (REF. 64) ; however, the lack of functional annotation for many genes can limit genetic studies. Metabolomic studies can help to overcome this shortcoming by enabling researchers to infer the function of genes 65 , providing further insights into biological pathways that could potentially be involved.
Some of the genetic variants identified by meta-analysis of GWAS datasets 56 lie in pathways known to be important in cartilage and bone physiology, such as CHST11, RUNX2 and IGFBP3; although for other variants, the gene function remains unknown. In situations where the mechanism linking a metabolite to disease onset or progression is known, it becomes feasible to make use of such a metabolite in clinical research. However, this knowledge is not necessary for a biomarker to be useful for diagnosis and prognosis, as is the case with anti-citrullinated protein antibodies, which are biomarkers for RA in routine clinical practice despite an incomplete understanding of their role in RA pathogenesis 66 . Figure 3 | Statistical approaches for the analysis of metabolomic data. After quality control of the metabolite data, analysis can focus on single metabolite associations with the trait of interest (univariate analysis), or the effects of multiple metabolites on the outcome being studied (multivariate analysis). Results can then be validated using different approaches and fed into network analysis. FDR; false discovery rate.
Combining metabolomics and genetics
A clear-cut example of the value of combining genetics and metabolomics is Mendelian randomization, a statistical technique that uses genetic variation related to a risk factor of interest to reassess observational estimates 67 . In this technique, the genetic variant acts as a proxy for the risk factor, and the random allocation of genes during gamete production and fertilisation (Mendel's second law) is used as a natural experiment to show causation 68 . Establishing a causal link between a metabolite and a disease or disease progression means that metabolite levels become directly relevant to disease management, and hence a target for intervention, rather than simply a by-product of disease. This is particularly relevant for diseases like OA, for which no disease-modifying drugs exist, despite the very high prevalence of the disease and unmet burden on healthcare systems.
GWAS show that, with the exception of the association of HLA molecules with autoimmune disorders, effect sizes for individual genes are modest and require large sample sizes (usually in the range of thousands). Conversely, metabolomic studies into rheumatic diseases require at most a few hundred individuals (TABLE 1; see  Supplementary information S1 (table) ). The use of data from both genetic and metabolomic studies is achievable. By querying GWAS data for variants that regulate levels of metabolites and by developing databases of metabolic profiles for various conditions (carried out on genotyped individuals), it will be possible to establish the links between genetic susceptibility to a given disease and alterations in metabolite levels in serum, urine, joint and bone tissues. Achieving this goal will require the replication of experiments in sufficiently large cohorts of patients with rheumatic disease who have been assayed for the same metabolite panels, with measurements taken at comparable time points (such as pretreatment or post-treatment). As these data become available, it will become possible to discover the genetic basis of links between the levels of certain metabolites and disease progression or response to therapy, and hence to understand the molecular pathways underlying these processes.
Future directions
In addition to biomarker discovery, metabolomic analyses can provide information on a patient's current medication use in the form of metabolites derived from specific drugs. If the drug dosage is known, then the levels of these metabolites can inform variation in drug response between patients or help track compliance in clinical trials. Metabolites can also provide information on smoking habits, as cotinine (a metabolic product of nicotine) is commonly measured in metabolomic panels.
Metabolomics concentrates on small molecules, but integrating other dynamic markers with this kind of data can enrich our understanding of pathogenesis and improve diagnosis, prognosis and disease management in the future. Here, we discuss two of these potential sources of data: proteomics and metagenomics.
Proteomics
The proteome encompasses all proteins expressed in a cell, tissue or organism, and as such is a dynamic reflection of both genes and the environment. The Human 69 . Proteomics is a promising field for biomarker research, as proteins are likely to be ubiquitously affected during disease and disease response.
Metagenomics
Despite GWAS and meta-analyses of GWAS using increasingly large samples, the variants identified account for 65% of the estimated heritability of RA 70 , and 3% of that of OA 71 . Structural variation, rare variants and environmental factors influenced by host genetics help to explain this 'missing heritability' . The microbial organisms that reside on and within a human host -the microbiome -is one such potential contributor 72 . Microorganisms produce a range of enzymes, chemicals, hormones and vitamins that can interact with our bodies. They also produce up to one third of the metabolites in human blood, and human genetic factors partially influence their presence in the gut 72 . Under physiological conditions, there is a mutually beneficial balance between intestinal bacteria and the host. Disruption of this intricate system (dysbiosis) is implicated in the pathogenesis of many human diseases, including RA 73 . Manipulation of the microbiome is relatively easy with dietary or probiotic interventions, making it an attractive target for therapeutic intervention 74 .
Conclusions
To date, no published studies exist that combine genetic and metabolomic approaches to understand the pathogenesis of rheumatic diseases. Largely, this reflects the scarcity of metabolomic studies into rheumatic diseases and the challenges posed by collecting relevant tissues (such as cartilage, bone and synovium) from patients and healthy individuals. Although genetic studies have delivered a remarkable wealth of knowledge into some rheumatic diseases, they have serious drawbacks, not least their non-dynamic nature and the modest effect sizes for GWAS-discovered non-HLA genes. Genetic studies also require very large sample sizes. Harnessing the power of both genetic knowledge and metabolomics is, however, achievable. By querying GWAS datasets for variants that regulate levels of metabolites, and by developing databases of metabolic profiles for various conditions (using genotyped individuals), it will be possible to establish the links between genetic susceptibility to a disease and changes in levels of metabolites. The combination of data from these techniques could help to identify the pathways that are most likely to change over time and to improve early diagnosis and identify risk of disease progression. As the price of metabolomic analyses decreases and the accurate measurement of hundreds of metabolites becomes feasible, metabolomics will be increasingly used in the clinic to assess the levels and efficacy of drugs in a patient's blood, and could rapidly replace the more expensive clinical tests used today.
